244 filings
Page 4 of 13
8-K
4ux 3a6ti972
5 May 21
Xencor Reports First Quarter 2021 Financial Results
4:02pm
DEFA14A
g8itpkyzrvj9 dxvr1v6
28 Apr 21
Additional proxy soliciting materials
4:16pm
8-K
1cnop6c
10 Mar 21
Departure of Directors or Certain Officers
4:24pm
8-K
k5iho2a1
23 Feb 21
Xencor Reports Fourth Quarter and Full Year 2020 Financial Results
4:01pm
8-K
7rb1h6qh1crcv vq
7 Dec 20
Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer
11:18am
8-K
ys4xbc1i8ztt
30 Nov 20
Entry into a Material Definitive Agreement
5:07pm
8-K
zu6lsqbw
5 Nov 20
Xencor Reports Third Quarter 2020 Financial Results
4:01pm
8-K
uvodv 5wh0pk5ed
14 Oct 20
Regulation FD Disclosure
5:19pm
8-K
l0on7 aqj1ahf36slo
4 Aug 20
Xencor Reports Second Quarter 2020 Financial Results
4:02pm
8-K
yg0n5c3nh02n7pn34i7d
26 Jun 20
Submission of Matters to a Vote of Security Holders
8:30am
8-K
tq5l4rh57
7 May 20
Xencor Reports First Quarter 2020 Financial Results
4:02pm
DEFA14A
y3fzvvo0q5bkoki6
29 Apr 20
Additional proxy soliciting materials
4:43pm
S-8
8xg8l 8jzbwi510agk
25 Feb 20
Registration of securities for employees
12:00am